VivoSim Labs shares are trading lower after the company announced that it priced a $4 million public offering.
VivoSim Labs Announces The Pricing Of Up To A $4M Best-Efforts Public Offering, With $3M Funded At An Initial Closing Of The Offering
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
VivoSim Labs Announces Its NAMkind Liver, Intestine Models Validated For Predicting Toxicity, Side Effect Profiles Of Antibody Drug Conjugates
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
VivoSim To Debut Antibody Drug Conjugate Data At Society of Toxicology Meeting
NIO Inc. Provides January 2026 Delivery Update
Market-Moving News for January 30th
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
VivoSim Labs shares are trading higher after the company announced it signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind toxicology services in liver and small intestine.
VivoSim Labs Signs JCBio As Authorized Distributor In Korea, Tekon Biotech In China For NAMKind Toxicology Services In Liver, Small Intestine
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
Did Record 2025 Deliveries and a Multi‑Brand EV Push Just Shift NIO's (NIO) Investment Narrative?
The Zacks Analyst Blog NIO, XPeng and Li Auto
NIO, XPeng & Li Auto Report December & Fourth-Quarter Delivery Results
NIO Posts Record December and Q4 Deliveries as 2025 Volumes Surge
How Investors Are Reacting To NIO (NIO) Surging November Deliveries Across Its Multi‑Brand EV Lineup
Nio Stock Slumps After Surprise November Delivery Drop
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.